Scarica l'app Stockscreener
99.32
1.17%
1.15
Dopo l'orario di chiusura:
99.32
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NUVL Giù?
Forum
Previsione
Nuvalent Inc Borsa (NUVL) Ultime notizie
Published on: 2025-11-02 23:09:14 - newser.com
Will Nuvalent Inc. stock rally after Fed decisionsWeekly Investment Summary & Community Consensus Stock Picks - newser.com
Can volume confirm reversal in Nuvalent Inc.2025 Technical Overview & Community Consensus Picks - newser.com
How risky is Nuvalent Inc. stock nowJuly 2025 Intraday Action & Fast Gain Stock Tips - newser.com
Published on: 2025-11-02 03:40:29 - newser.com
Why analysts remain bullish on Nuvalent Inc. stockJuly 2025 Analyst Calls & Free Accurate Trade Setup Notifications - newser.com
Statistical indicators supporting Nuvalent Inc.’s strengthWeekly Gains Summary & Daily Chart Pattern Signals - newser.com
Can Nuvalent Inc. stock outperform in 2025 bull marketMarket Risk Analysis & Trade Opportunity Analysis Reports - newser.com
Nuvalent (NASDAQ:NUVL) Insider Deborah Ann Miller Sells 21,800 Shares - MarketBeat
Applying sector rotation models to Nuvalent Inc.Weekly Trading Summary & Pattern Based Trade Signal System - newser.com
What data driven models say about Nuvalent Inc.’s future2025 AllTime Highs & High Accuracy Swing Trade Signals - newser.com
Will Nuvalent Inc. bounce back from current supportPortfolio Performance Report & Free Accurate Trade Setup Notifications - newser.com
Analysts Have Conflicting Sentiments on These Healthcare Companies: Edwards Lifesciences (EW), Centene (CNC) and Nuvalent (NUVL) - The Globe and Mail
Nuvalent Inc Reports Q3 2025 EPS of -$1.70, Missing Estimates; S - GuruFocus
What moving averages say about Nuvalent Inc.July 2025 Update & Breakout Confirmation Trade Signals - newser.com
Nuvalent price target raised to $120 from $105 at Goldman Sachs - TipRanks
Nuvalent (NASDAQ:NUVL) Announces Earnings Results - MarketBeat
Barclays Raises Price Target for Nuvalent (NUVL) to $112.00 | NU - GuruFocus
Nuvalent stock price target raised to $132 by UBS on cancer drug progress - Investing.com Canada
Nuvalent price target raised to $132 from $114 at UBS - TipRanks
Analysts Are Bullish on Top Healthcare Stocks: TransMedics Group (TMDX), Nuvalent (NUVL) - The Globe and Mail
Using economic indicators to assess Nuvalent Inc. potential2025 Stock Rankings & Long-Term Safe Investment Plans - newser.com
Why Nuvalent Inc. stock is trending among retail traders2025 Investor Takeaways & Growth Focused Stock Pick Reports - newser.com
Nuvalent, Inc. Reports Q3 2025 Progress and Financials - TipRanks
Decoding Nuvalent Inc (NUVL): A Strategic SWOT Insight - GuruFocus
Insider Selling: Nuvalent (NASDAQ:NUVL) Director Sells $1,437,799.35 in Stock - MarketBeat
Insider Selling: Nuvalent (NASDAQ:NUVL) Director Sells 32,455 Shares of Stock - MarketBeat
FY2026 EPS Estimates for Nuvalent Decreased by Analyst - MarketBeat
Nuvalent’s Cash Cushion Keeps Investors On Board Through Setbacks - Finimize
Nuvalent Q3 Net Loss Widens - MarketScreener
Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2025 Financial Results - The Malaysian Reserve
Custom strategy builders for tracking Nuvalent Inc.Portfolio Value Summary & Verified Swing Trading Watchlist - newser.com
Nuvalent (NASDAQ: NUVL) completes zidesamtinib NDA; cash runway anticipated into 2028 - Stock Titan
Nuvalent’s Zidesamtinib Study: A Potential Game-Changer in Cancer Treatment - The Globe and Mail
Nuvalent (NASDAQ:NUVL) Reaches New 12-Month HighShould You Buy? - MarketBeat
Nuvalent (NUVL): Reassessing Valuation Following New Clinical Trial Data on Neladalkib - Sahm
1.62%
0.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):